Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement

Yoshimi Nabe; Shohei Kikuchi; Yusuke Kamihara; Akinori Wada; Jun Murakami; Tsutomu Sato

doi:10.1002/ccr3.4657

Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement

Clin Case Rep. 2021 Aug 16;9(8):e04657. doi: 10.1002/ccr3.4657. eCollection 2021 Aug.

Authors

Yoshimi Nabe^{1

2}, Shohei Kikuchi¹, Yusuke Kamihara¹, Akinori Wada¹, Jun Murakami³, Tsutomu Sato¹

Affiliations

¹ Department of Hematology Toyama University Hospital Toyama Japan.
² Center for Medical Residency Training Toyama University Hospital Toyama Japan.
³ Division of Transfusion Medicine and Cell Therapy Toyama University Hospital Toyama Japan.

Abstract

Evaluation of early response by flow cytometry and immunogloblin heavy chain assessments against primary bone marrow B-cell lymphoma could be valuable for predicting treatment outcome.

Keywords: IGH rearrangement; primary bone marrow B‐cell lymphoma; rituximab‐based CHOP.

Publication types

Case Reports